



HHS Public Access

Author manuscript

J Allergy Clin Immunol. Author manuscript; available in PMC 2021 January 01.

Published in final edited form as:

J Allergy Clin Immunol. 2020 January ; 145(1): 28–37. doi:10.1016/j.jaci.2019.11.012.

Advancing Patient Care Through the Consortium of Eosinophilic Gastrointestinal Disease Researchers

Seema Aceves, MD, PhD¹, Margaret H. Collins, MD², Marc E. Rothenberg, MD, PhD³, Glenn T. Furuta, MD⁴, Nirmala Gonsalves, MD⁵, Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)*

¹Division of Allergy Immunology, University of California, San Diego, Rady Children's Hospital, San Diego: 9500 Gilman Drive, La Jolla, CA, 92093, USA

²Division of Pathology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine: 3333 Burnet Avenue, Cincinnati, OH, 45229, USA

³Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine: 3333 Burnet Avenue, Cincinnati, OH, 45229, USA

⁴Digestive Health Institute, Children's Hospital Colorado, Gastrointestinal Eosinophilic Diseases Program, University of Colorado School of Medicine: 13123 East 16th Avenue, Aurora, CO, 80016, USA

⁵Division of Gastroenterology, Northwestern University Feinberg School of Medicine: 303 East Chicago Avenue, Chicago, IL 60611, USA

Abstract

Recent advances in rare diseases research are accelerated by the work of consortia that have been supported by the National Institutes for Health. Development of such consortia rely on multi-disciplinary relationships and engagement with patient advocacy groups as well as the NIH, industry and academic partners. In this Rostrum, we present the development of such a process that focuses on eosinophilic gastrointestinal diseases (EGIDs). Principal investigators, patient advocacy groups, research assistants and trainees work together to perform natural history studies that promote clinical trial readiness tools, conduct clinical trials, train a new generation of investigators and perform innovative pilot studies.

Keywords

Eosinophils; Gastrointestinal; Consortium; Allergy; Esophagitis; Advocacy

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Address Correspondence to: Glenn T. Furuta, MD, Digestive Health Institute, Children's Hospital Colorado, Gastrointestinal Eosinophilic Diseases Program, University of Colorado School of Medicine: 13123 East 16th Avenue, Aurora, CO, 80016, USA; Glenn.Furuta@childrenscolorado.org. 720-777-7457.

Why are eosinophils present in the normal gastrointestinal tract?

The gastrointestinal tract is a series of four organs, separated by a series of sphincters, that are defined by unique structures and specific functions. The gastrointestinal tract is normally hypoxic, regularly encounters a myriad of food particles, and houses the most concentrated microbial commensal flora compared with that of other regions of the body. Within this diverse cellular and metabolic environment quietly resides the bilobed granulated leukocyte, the eosinophil. Eosinophil levels increase along the length of the gastrointestinal tract, going from none in the esophagus to the maximal number within the colon. A few studies have determined the “normal” numbers of gastrointestinal eosinophils in mucosal and full thickness biopsies taken from adults and children without identifiable gastrointestinal inflammation. (1, 2) Because eosinophils normally reside in the mucosa, it is likely that they play a role in innate host defense. Though this has yet to be fully determined, evidence is emerging that gastrointestinal eosinophils have the capacity to regulate local immunoglobulin production, intestinal microbial content, epithelial barrier function and killing of intraluminal parasites.(3)

Defining eosinophils’ pathologic role in the gastrointestinal tract is challenging

In 1937, the German surgeon Kaisjer described key features of selected, full-thickness, eosinophil-rich surgical resections of gastrointestinal tissues and thus provided a unique view of patients with gastrointestinal symptoms and a previously underrecognized type of inflammation.(4) Over the next 50 years and with the advent of flexible gastrointestinal endoscopy and procurement of mucosal biopsies, case series provided further documentation of the clinical features reported by patients who were affected by dense gastrointestinal eosinophilia. Patients’ symptoms and endoscopic findings were non-specific, and histologic features were characterized primarily by an increased density of eosinophils, with numbers of eosinophils provided only intermittently. No other eosinophil-promoting diseases, such as parasites, cancer or, inflammatory bowel diseases, were identified, and these patients were therefore described as having an eosinophilic gastrointestinal disease (EGID).(5, 6)

Because the gastrointestinal tract normally contains eosinophils, the major problem in the descriptions of these patients was determining what defined an abnormal number and distribution of eosinophilia; whether other features of the eosinophilia, such as degranulation, were critical to assess; and, perhaps as importantly, whether or not other inflammatory features were present in epithelial surfaces or submucosal spaces. Factors that contributed to difficulties in assessing these issues include the fact that EGIDs are rare; diagnoses required costly, time-consuming, sedated endoscopic procedures; biopsies captured a limited amount of the mucosal surface; densely packed eosinophils were difficult to count; states of degranulation were challenging to quantify; and the presence of extracellular granules could result from mechanical disruption of eosinophils. In fact, a trend toward overdiagnosis ensued. Attempts to characterize patients with EGID were further stymied because peripheral and stool biomarkers did not always represent local

gastrointestinal mucosal activities. Thus, in many ways and for numerous reasons, the enigmatic eosinophil escaped deeper understanding in health and disease.

Eosinophilic gastrointestinal diseases are increasingly recognized

The increasing availability of endoscopic procedures has augmented our knowledge about EGIDs, and the diagnosis of EGID has been made more frequently.(6) Patients with gastrointestinal symptoms, such as heartburn, abdominal pain, or diarrhea, received the common diagnoses of gastroesophageal reflux disease, peptic disease, or irritable bowel syndrome. However, if their condition did not improve with standard therapy, they underwent diagnostic endoscopic assessment. Some of these patients were found to have mucosal biopsies with increased eosinophils. After exclusion of other causes of the histologic findings, a diagnosis of eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic gastroenteritis (eosinophilia involving multiple segments of the intestine) (EGE), or eosinophilic colitis (EC) was made. Because eosinophilia in industrialized countries is associated with allergy and initial pediatric studies of EoE demonstrated food antigens as disease triggers, collaboration with allergists increased. Though the initial goal was primarily to identify triggering food antigens, the current role of the allergist in EoE is to provide EoE management, define potential EoE triggers, and control concurrent atopic diseases that can exacerbate EoE.(7–9)

Progress with eosinophilic esophagitis

Although progress can never occur quickly enough for patients, the development of EoE diagnostic criteria and implementation of EoE treatment paradigms has transpired at a remarkable pace. Prior to 1995, EoE was a clinical rarity, limited primarily to important case series. (10, 11) Over the course of the next decade, reports published by adult and pediatric allergists, radiologists, gastroenterologists and pathologists provided important insights into key clinical features and potential pathogenic mechanisms. Collaborative works coalesced in a working group called TIGERS (The International Gastrointestinal Eosinophil Researchers), which was supported by the Bunning Family, and acted as an incubator to address clinical needs. A yearlong TIGERS project that was performed in collaboration with the American Gastroenterological Association and North American Society of Pediatric Gastroenterology, Hepatology, and Nutrition resulted in the publication of the first EoE diagnostic criteria in 2007.(12) In 2008, the advocacy group the American Partnership for Eosinophilic Disorders (APFED, <https://apfed.org>), succeeded in gaining approval of ICD codes for EGIDs. Retrospective clinical studies identified innovative approaches, including clinical assessment tools, and treatment while basic research determined pathogenetic pathways and novel therapeutic targets. Together these studies encouraged development of clinical outcome metrics and eventually prospective clinical trials.

This progress of the last 2 decades was sustained because of many factors (Table 1), not the least of which was relationships formed between collaborative researchers and patient advocates who willingly and intentionally engaged together to develop and execute a plan to improve the lives of patients affected by EoE. In these efforts, patients of all ages, advocates from different backgrounds, pediatric and adult researchers representing different specialties,

industry partners, a number of academic societies, and the NIH have worked together to develop diagnostic criteria, identify clinical outcome metrics (COMs), and perform clinical trials.(13)

Remaining challenges in studying EoE and other EGIDs

The rarity of EGIDs creates at least 2 problems related to advancing care. First, as a part of their daily practice, clinicians may not recognize EGIDs in a timely fashion; in fact, some studies indicate that there can be a diagnostic delay from symptom onset to diagnosis of up to 6 years.(14, 15) This delay limits the ability to offer proper consultation, provide appropriate treatment and prevent complications. Second, therapeutic studies may experience slow enrollment because of the rarity of EGIDs, burden of a number of endoscopic procedures, distance and time needed to travel to clinical sites, and lack of interest in enrolling in a placebo-controlled study. To combat these issues, studies often require large numbers of enrolling sites, and this is associated with increased financial startup costs. In addition, the same patients can be repeatedly approached for various new studies.

Although patient-reported outcomes (PROs) and COMs have been developed for EoE, no validated metrics currently exist for EG, EGE, and EC. Correlation of PROs and COMs with histologic features and eosinophil numbers continues to be an area of investigation. Furthermore, developing better methods to detect eosinophils in gastrointestinal tissues, identifying specific peripheral biomarkers that relate to tissue eosinophilia, and defining the pathogenetic role that eosinophils have in these diseases are areas of clinical and research needs. EG, EGE, and EC diagnostic criteria have not been fully vetted, and in some situations, this has hindered clinical trials in the non-EoE EGIDs.

Finally, the pace of basic studies that will identify pathogenic mechanisms and therapeutic targets has been slowed because of limited numbers of animal models and eosinophil cell lines, challenges in isolating and studying human eosinophils, and practical difficulties related to procuring intestinal samples from patients with EGIDs and controls. The development of novel model systems including organoids and ex vivo functional human mucosal platforms will hopefully lead to novel ways to study EGIDs.(16)

Development of a Consortium to improve care of patients with EGIDs

In order for treatments to effectively reach patients with EGIDs, several different milestones need to be achieved. Increasing awareness of EGIDs is imperative so that affected patients can receive diagnosis and treatments and natural history can be tracked. This relies not only on educating established health care professionals but also educating new trainees and students. Developing diagnostic guidelines, creating PROs and COMs, identifying therapeutic targets, and completing clinical trials are major achievements that must be met for patients to receive better care.

To address the needs of patients affected by rare diseases, the National Institutes of Health and its Office of Rare Diseases Research, developed the Rare Diseases Clinical Research Network (RDCRN), using a cooperative U54 grant mechanism, in order to accelerate the

completion of therapeutic trials. The RDCRN has been composed of a selected number of consortia, each focused on a distinct set of at least three related rare diseases. Required elements for each consortium included a natural history study, clinical trial study, pilot studies, a training module, and partnership with at least one patient advocacy group (PAG).

The RDCRN funded the Consortium for Eosinophilic Gastrointestinal Disease Researchers (CEGIR) in 2014 (CEGIR1, 2014–2019) and renewed this funding in 2019 (CEGIR2, 2019–2024) (CEGIR, <https://www.rarediseasesnetwork.org/cms/CEGIR>). NIH funding for CEGIR is derived from the National Center for Advancing Translational Sciences, National Institute of Allergy and Infectious Diseases, and National Institute of Diabetes, Digestive and Kidney Diseases. In addition to involving 18 academic institutions in the USA, 1 collaborative site in Switzerland, and 3 main PAGs, CEGIR collaborates with a number of professional organizations and commercial entities and has an external advisory board. In contrast to previous publications, this ROSTRUM focuses on some of the key elements needed to develop a research consortium. (17–19). Other CEGIR related reviews have focused on overall structure of CEGIR, as laid out in Figure 1, and on the working logistics and products.

CEGIR aims to address 3 concerns. First, because these eosinophilic diseases are rare and relatively newly recognized, few validated COMs exist, and knowledge concerning the natural history of EGIDs is limited. Thus, the Outcome Metrics for Eosinophilic Gastrointestinal diseases across the Ages (OMEGA) was designed to meet these concerns directly and to address the concept of clinical trial readiness. During CEGIR1, OMEGA enrolled nearly 900 patients from across the country who had EGIDs, including EoE, EG, and EC, and tracked their clinical, endoscopic, histologic, and molecular features. To date, OMEGA has allowed development of novel COMs for EG, been instrumental in the development of histologic and endoscopic COMs for EoE and defined molecular endotypes of EoE and EG.(20, 21) During CEGIR2, OMEGA will continue to follow patients to further understand the natural history of EGIDs and develop diagnostic criteria for EG, EGE, and EC; establish COMs for EG, EGE, and EC; and provide deeper understanding regarding the molecular underpinnings of these EGIDs.

Second, the rarity of EGIDS and the lack of adequate attention to it in most medical training has resulted in a lack of recognition of these diseases and a limited number of providers who have significant clinical experience with EGIDs. To address these concerns, the CEGIR1 Training (Career Development) Program developed a robust mentoring and research experience for junior faculty trainees, who presented 58 abstracts and posters, published 23 manuscripts and accrued \$4.6 million in grant funding. Selection of trainees was competitive and based not only on credentials, but also location of practice in order to provide training in areas of geographic need. In CEGIR2, the Career Enhancement Core will further extend this training with medical school and postgraduate trainees, with an emphasis on virtual training and face-to-face mentoring.

Third, because EGIDs are early in their research history, novel and innovative pilot projects are needed to advance care and knowledge. During CEGIR1, pilot studies of the Pilot/Demonstration Clinical Research Program examined the microbiome of EGIDs, impact of a

potential anti-fibrotic agent (losartan) in EoE, the kinetics of mucosal eosinophilia during food reintroductions with the transnasal endoscopy, and the impact of an elemental diet on EG. The CEGIR2 Pilot-Feasibility Core will select pilots that will utilize data accrued by OMEGA, provide rapid and high-impact findings, and/or promote engagement with PAGs.

Value of multidisciplinary approach in CEGIR

The EGID field has advanced relatively rapidly because of the close collaboration of physician-scientists who are closely aligned with patient advocates.(13, 19, 22–24) In this realm, CEGIR is composed of a unique and extensive network of pediatric and adult allergists, gastroenterologists, pathologists, statisticians, an epidemiologist, and advocates from across the world.(17, 18) All have taken active roles within CEGIR, and successful execution of the mission of CEGIR is done with proper synergy with all the invested disciplines. Each member of the consortium has an important role, and successful outcomes have been accomplished with this much needed balance. Below is a summary of how each has contributed to advance EGID research.

Allergists

Pediatric and adult allergists from numerous different institutions share in contributing their expertise to CEGIR. Their expertise and dedication has provided key guidance in developing novel treatments and addressing important questions related to atopy. In addition, leadership for CEGIR has been shared between disciplines in order to assure that the needs of various specialties are addressed.

Clinical Impacts—Because EoE is a disease with type 2 allergen-mediated inflammation, allergists have an integral and vital role in clinical care.(7–9) First, it is not unusual that an allergist may be the first to suspect EGID in a patient. As a part of the highly atopic patient’s medical history and review of symptoms, subtle or overt gastrointestinal symptoms may be identified and thus prompt a referral to a gastroenterologist for evaluation and potential endoscopy. Second, when a diagnosis of EGID is confirmed, treatments with diet elimination and topical steroids are instituted, and the execution of this plan often is best served by an allergist. Because of the clinical challenges posed by EGIDs, including the interplay between multiple atopic diatheses in the same person and immunologic complexities, clinical collaboration of allergists with gastroenterologists creates benefit for patients and families. For instance, a toddler with asthma, atopic dermatitis, EoE, peripheral eosinophilia, and adrenal insufficiency who is on topical steroids for all their diseases will require close communications between specialties as to how to successfully manage the intricacies of each disease and complications. Finally, identifying and treating co-morbid diseases that promote healing of all affected mucosal surfaces can only benefit patient healing and potentially help with maintenance of remission. Within CEGIR, considering these types of issues allows for increasing subject enrollment into trials, a focus to understand how allergic manifestations and treatments can be managed, and collaborative studies to unravel the meaning of atopic signals.

Research—Clinical and basic scientists who focus on atopic diseases have long sought answers of how to measure disease activity associated with, define the underlying mechanisms of, and treat patients affected by Th2- and eosinophil-related diseases. Their efforts led to development of EoE-related COMs, studies addressing the utility of skin testing for suspected EoE food allergens, therapeutic trials identifying dietary approaches to EoE treatment, and the discovery of the novel use of a topical steroid preparation for EoE. (20, 25–28) Basic studies identified EoE-related genes, molecular pathways, and therapeutic targets for EoE and EG and developed novel research platforms in the form of diagnostic panels. (29–34) One of the most significant contributions made by allergists to the EGID field relates to studies examining the role of biologics targeting molecules related to eosinophilia. For instance, the use of anti-IL-5, approved for severe asthma, and IL-4/–13 receptor blockade with dupilumab, approved for severe asthma and eczema, have been trialed in EoE. (35–37)

In addition, a number of key clinical features and research topics related to atopy require greater understanding. Is there a role for skin and blood testing for food allergens that may evoke EoE? How can we test for EoE-related food allergens? What is the impact of aeroallergens on the exacerbation of EoE? Are there common pathways linking EoE with other allergic diseases? Should COMs related to allergic diatheses be included in the therapeutic assessment of patients with EGIDs? What is the role of allergens in EG, EGE, and EC? Are there predisposing factors that may contribute to the generation of EGIDs? Some of these questions are being pursued in the context of CEGIR.

Gastroenterologists

Pediatric and adult gastroenterologists from numerous different institutions participate in the collaborative research in CEGIR. Because patients with an EGID diagnosis must undergo an endoscopy, their initial evaluation is performed by a gastroenterologist. In this regard, gastroenterologists are typically most familiar with their presenting symptoms related to swallowing and eating and associated endoscopic features and thus have a critical role in identifying EGIDs in patients in general and subspecialty gastroenterology practices, developing COMs as they pertain to presenting symptoms and endoscopic features, and creating novel metrics to assess the gastrointestinal tract. In addition, sharing observations with others at international platforms permits increased understanding and recognition of EGIDs.

Clinical Impacts—EGID diagnoses are made by gastroenterologists after clinical suspicion has been raised and endoscopic evaluation with mucosal biopsy has been completed. Because EGIDs are defined as clinicopathologic diseases, gastroenterologists are typically on the front line of establishing the initial diagnoses. In this regard, since symptoms related to swallowing are typically addressed primarily by gastroenterologists, they have helped clarify and identify coping skills with respect to eating some foods. (38–40) For instance, many children and adults may compensate for their dysphagia by lubricating food during meals with water or sauces or exhibit prolonged chewing of highly textured foods.

The gastroenterologist's role with respect to endoscopic evaluation has been 2 fold. First, endoscopy must be performed to collect a mucosal pinch biopsy and provide a visual assessment of the mucosa. Second, if esophageal strictures and narrowings develop as a consequence of excessive fibrosis and remodeling, therapeutic dilations are often needed in order to improve swallowing. Over the course of the past decade, technical aspects of this intervention have become more and more refined as they are different from the dilation of the more commonly encountered peptic strictures.

Gastroenterologists have also made strides in the clinical implementation of topical steroids and dietary restriction. With respect to the latter, the description of the 6-food elimination diets for EoE was led by adult and pediatric gastroenterologists.(41–45) In addition, they have related strategies for implementing a dietary plan, the impact of the diet treatment on quality of life, and need for maintenance therapy.(46–48)

Research—Because of the unique view offered by endoscopic assessment, gastroenterologists have provided several important research roles. Detailed inspection of the esophageal mucosa led to the development of a COM for EoE. The EoE Reference Score (aka EREFS) provides a validated system to assess the common endoscopic features of EoE —Exudate, Rings, Edema, Furrows, and Strictures. (49) The EREFS can be used to assess disease activity in both pediatric and adult patients with EoE to monitor disease activity and/or therapeutic efficacy. (21, 50–52) We are hopeful that endoscopic scoring for EG, EGE, and EC, similar to the EREFS system created for EoE, will be developed over the course of CEGIR2.

The art of dilation in EoE has been increasingly described and characterized. Adult gastroenterologists are typically more experienced with esophageal dilation and, in a number of research platforms, have helped to inform pediatric practitioners and others on the subtle differences in dilating the fibrotic organ. (53–58) In addition, because of the visualization and clinical impact of EoE on barrier and fibrosis, gastroenterologists have embarked on basic studies to understand their basic mechanisms.(59–62)

Finally, devices that have been developed to interrogate the esophagus in other diseases or other parts of the gastrointestinal tract have been now brought to use in research studies focused on EoE. Examples of these include the mucosal impedance probes for measuring reflux, the string test for detecting intestinal parasites, the cytosponge for detecting Barrett's esophagus, confocal microscopy, endoflip for detecting distensibility, transnasal endoscopy and others, which have now all been repurposed for use in tracking EoE activity and understanding the pathogenesis of EoE.(63–68)

Pathologists

Pediatric and adult pathologists from 3 different institutions contribute their shared expertise to CEGIR. Their expertise and dedication provides key guidance to both measuring and understanding the key histologic features of mucosal biopsies from patients with EGIDs, as well as those of healthy controls.

Clinical Impacts—The evaluation of mucosal biopsies and, in some cases, full-thickness biopsies remains a key component to making the diagnosis of EGIDs. The diagnostic biopsy is assessed in numerous ways, including to determine whether other histologic elements are supportive of other diagnoses that may have eosinophilia as a feature, such as inflammatory bowel diseases or infections. For example, prior to the recognition of EoE, esophageal biopsies from children that contained no or scattered eosinophils were diagnosed as gastroesophageal reflux disease (GERD), and biopsies that contained abundant eosinophils were diagnosed as marked GERD! Pediatric gastroenterologists consulted pediatric pathologists at conferences or across the microscope about their patients who were not responding to anti-reflux therapy. These consultations led to the recognition of a non-GERD disease affecting the esophagus, and sharing images of esophageal endoscopies and the corresponding biopsies at a weekly conference led to the first description of endoscopic abnormalities in EoE.(69) Observations made by pathologists in their daily practice led to publications that consistently cited 15 eosinophils per high power field in biopsies from patients with esophageal symptoms who did not have GERD or who responded only incompletely to anti-reflux therapy, which remains the gold standard for the pathology portion of the clinicopathologic diagnosis of EoE.(12) More recently, pathologists reported reduced numbers of or no eosinophils in biopsies following proton pump inhibitor (PPI) therapy. Most of these pathologists reviewed such biopsies blinded to current therapy which is generally not included in pathology requisitions, and this information led to the recent recommendation that PPI are therapy for EoE rather than using PPI refractoriness as part of the diagnostic criteria. (70)

Understanding the day to day aspects of clinical practice are key to developing standardized approaches toward the assessment of mucosal biopsies. For instance, in some busy clinical practices pathologists face a difficult task when asked to rule out EGIDs in the hematoxylin- and eosin-stained sample. The laborious tasks of identifying the location with the peak eosinophil infiltration and counting eosinophils, especially when they are found in sheets or within a sea of eosinophilic granules, may not always be efficient or feasible. Identifying key features, such as eosinophilic abscesses, degree of degranulation, distribution along the gastrointestinal tract, and patterns of eosinophilia, is helpful in the tissue characterization and for post treatment analyses. Gastroenterology and allergy colleagues rely on these numbers to frame the clinical features in the proper fashion. For instance, large numbers of eosinophils may be present in the lamina propria, but when found in the setting of larger numbers of polymorphonuclear cells, epithelial erosions, and ulcers and crypt abscesses in the colonic mucosa, the diagnosis is likely ulcerative colitis. The experienced assessment of the entire tissue can provide supportive evidence of whether the inflammatory process appears to be chronic or acute.

Research—Over the course of the last decade, pathologists continue to help the EGID field mature by increasing the analytical metrics for EoE. Early EoE studies were primarily limited to noting the presence and, in some cases, counting eosinophils. Now, a robust scoring system, the Histologic Scoring System, has developed that includes additional features with respect to EoE that, in addition to eosinophil density, includes basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces,

thickened lamina propria fibers, surface epithelial alterations, and dyskeratotic epithelial cells. (71) Each of these features is examined for severity (grade) and extent (stage), and a total score is assigned. The system has strong interobserver reliability and revealed that basal zone hyperplasia and dilated intercellular spaces correlated strongly with treatment status. In addition, symptoms scores correlated with pathology scores in children enrolled in CEGIR1. (20) These key observations provide additional support for mechanistic studies and clinical studies showing that despite resolution of eosinophilia, some patients may continue to experience symptoms and basal zone hyperplasia. More comprehensive evaluation of biopsy pathology could potentially suggest new targets for therapy, such as epithelial hyperplasia, and dilated intercellular spaces which might impact epithelial barrier function. Pathologists may contribute to the development of new therapies by participating in randomized clinical trials, including those sponsored by pharmaceutical companies since FDA-approved therapies are still lacking. (72) In such studies pathologists may provide central pathology review that reduces variability and provides quality assurance of the diagnosis at baseline. CEGIR pathologists participated in a randomized trial of dietary therapy to treat EoE and the results will be soon available.

As with the allergists, pathologists in the EGID field have many questions to be addressed—Are there biomarkers or molecular signatures in the tissue that can differentiate EGIDs from other eosinophil-associated diseases? How can eosinophilia be quantitated in a rapid fashion as a part of a busy clinical practice? Is there a value for artificial intelligence in evaluating clinical specimens following WSI? What are the histologic features associated with EG, EGE, and EC? Are there different phenotypes or endotypes of the EGIDs, as there appears to be with EoE? What are the ways that more of the gastrointestinal mucosa can be assessed histologically? Can deeper layers of the GI tract such as the muscularis propria be safely biopsied endoscopically to identify inflammation in the deeper layers of patients who have persistent symptoms but not persistent mucosal eosinophilia?

One of the major contributions of pathologists that occurred during the course of CEGIR1 relates to establishing novel approaches for pathologists to economically and reliably analyze tissue slides. Initial enrollment in OMEGA1 was based on the local pathologists' assessment of mucosal biopsies. The 3 CEGIR pathologists reviewed entry biopsies to ensure that they met enrollment criteria. This approach provided the consortium with a thorough assessment by experienced adult and pediatric pathologists at different geographic locations (Cincinnati, Chicago, and Denver) who could identify eosinophilia and other features in patients with these rare diseases. However, this approach posed a significant logistical concern—how would 3 pathologists at 3 different institutions analyze hundreds of slides in a reasonable time frame and accommodate regulatory and cost concerns?

This issue drove the development of an innovative research platform for the RDCRN and its associated Data Management and Coordinating Center (DMCC); the patients' slides were locally scanned at the time of study entry or centrally scanned at the time of study entry. The images were then stored in a safe and accessible virtual bank for pathologists to access and analyze; this process is referred to as whole-slide imaging system that relies on digital microscopy following scanning of clinical biopsy slides. This not only provides an opportunity for convenient use of virtual microscopy using standardized procedures, but also

has generated an EGID pathology slide database (using secure cloud services) that is available for educational and sharing purposes.(17) Development and execution of this plan provided CEGIR with a new resource that saved time and money and met compliance and provide pathologists' in other fields of study with an alternative for collaborative study platforms.

Patient Advocacy Groups (PAGs)

Collaboration with PAGs is critical to any research. During CEGIR1, PAGs [APFED, CURED-curedfoundation.org, and the Eosinophil Family Coalition (EFC, www.eoscoalition.org)] played a critical role in its success and refunding. Their participation in CEGIR committees and conference calls, attendance and presentations at annual meetings, and contribution of services and time to the RDCRN patient advocacy steering committee created an increased awareness of patients' needs. In addition, they provided key advice on study designs and protocols regarding challenges in enrollment and adherence. The patient advocacy groups APFED and CURED have successfully raised substantial funds which has been distributed to EGID investigators for the purpose of advancing EGID-related research. Bestowing financial support, advertising clinical studies to a wide group of patients, and publicizing key research findings provided valuable services that would not be possible with an investigator-only consortium. Finally, CEGIR investigators and PAGs united forces at annual patient meetings to present CEGIR-related research and meet patients and families in one-on-one settings. These relationships provide patients and families with opportunities to ask direct questions to investigators and for investigators to learn more about the leading questions needing to be answered from the patient perspective and how to develop and execute patient-friendly research.

Consortium challenges and solutions

Challenges related to working in a consortium are not unique to EGIDs and relate to those that would affect any diverse group of advocates, clinicians, and researchers who are dispersed across different time zones, supported by a variety of different resources, and are at different professional stages in their careers. Practical challenges for patients to enroll in studies and adhere to protocols may not be recognized. The costs and environmental restraints of performing endoscopies and skin testing are not always obvious. The research infrastructure and financial support to carry out studies varies significantly between sites. Investigators' professional aspirations and requirements for independence as it relates to academic promotions and publications may be supplanted by the needs of the group. Organizing meetings and teleconferences so that people are able to complete other duties and not interfere with personal time is challenging. Communications and inclusivity of all members regarding planned changes in protocols, opportunities for participation in activities and events, and publications creates concerns. Finally, utilizing a centralized IRB and understanding layers of regulatory and compliance aspects pose a different set of hurdles not always experienced in single-site or local studies.

Despite these challenges, CEGIR continues to thrive as a group and address its mission by ensuring 1) a consistent stream of communications, 2) transparency in budgets, plans, and

goals, 3) diversification of leadership roles, 4) provision of opportunities for professional growth, 5) access to data and samples, 6) preservation of a spirit of collaboration, collegiality, and inclusivity, 7) provision of opportunities for individuals to promote and carry out their own innovative research ideas, often involving data and biospecimen sharing, and 8) use of CEGIR data and its derivatives (data) as a springboard for other research projects and grant applications. PAG and multidisciplinary discussions are vital to ensure that studies are designed and executed in a patient-friendly fashion and that practical and logistical concerns are addressed early on. Bi-monthly “All Calls “ are held to inform of CEGIR progress and educate members on areas of expertise. Goals and plans are discussed regularly by committee and presented at annual meetings held at the NIH. Senior investigators involve junior investigators in the various studies to help further their research career in a mutually beneficial fashion. Samples and data are quality assured and monitored by the DMCC, and use is monitored by CEGIR committee. Annual surveys are conducted to identify areas of strength and need. Together, these help CEGIR to execute and complete research studies in a reasonable time frame.

Future for eosinophilic gastrointestinal diseases

It is rare for anyone involved in medicine to be able to be involved in the early stages of the “history” of a disease, and in fact, most of the content described here has been developed in the last 25 years. The relative newness of EGIDs to the medical landscape speaks to the immense opportunities available that will shape the field for decades to come and that can improve the lives of patients in a relatively rapid manner. Research emanating from CEGIR2 will include further characterization of non-EoE EGID, (73) with a particular emphasis on developing consensus guidelines for these disorders, pursuing a randomized clinical trial with novel biologic therapy for EGID, and supporting innovative pilot studies. Access to CEGIR research studies can be found at the CEGIR website <https://www.rarediseasesnetwork.org/cms/CEGIR> and further information regarding biologics are summarized in recent publications. (74) Training of future leaders and investigators in this field is also at that forefront of CEGIR2. The NIH/RDCRN U54 Consortium opportunity provides a unique chance to participate in these advances on behalf of our patients and their families. In parallel, CEGIR will synergize with the many other research studies that will continue to advance the EGID field that will provide more data that identify key clinical features, endoscopic abnormalities, histologic findings, and impacts on quality of life. Developing novel devices and approaches to detect disease activity and establishing peripheral biomarkers to monitor patient’s progress will reach a higher degree of maturity. Discovery of pathogenetic pathways and novel therapeutic targets will forge new treatments and approaches for patients with EGIDs. CEGIR will promote future progress in the EGID field and clinical practice by sharing of the CEGIR database and the growing biorepository of over 5,000 samples that are linked to clinical information; CEGIR data sharing and scientific advisory committees are in place to facilitate these processes.

Acknowledgements

The authors are supported by the Consortium for Eosinophilic Gastrointestinal Diseases Researchers (CEGIR) (U54 AI117804). CEGIR is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), NCATS, and is funded through collaboration between NIAID, NIDDK, and

NCATS. CEGIR is also supported by patient advocacy groups including American Partnership for Eosinophilic Disorders (APFED), Campaign Urging Research for Eosinophilic Diseases (CURED), and Eosinophilic Family Coalition (EFC). GTF is also supported by LaCache Chair in Gastrointestinal Allergic and Immunologic Diseases Chair of Pediatrics. We thank Shawna Hottinger for editorial assistance.

Conflicts of Interest/Disclosures

S.S.A. is a consultant for Regeneron, AImmune Therapeutics, and Gossamer; is an inventor of oral viscous budesonide, patented by UCSD and licensed by Shire/Takeda; and has research funding from the Ferring Research Institute.

M.H.C. is a consultant for Shire, Regeneron, Receptos, and Esocap and has received research funding from Shire, Regeneron, and Receptos.

M.E.R. is a consultant for Pulm One, Spoon Guru, ClostraBio, Celgene, Astra Zeneca, and Allakos, and has an equity interest in the first three listed, and royalties from reslizumab (Teva Pharmaceuticals), PEESV2 (Mapi Research Trust) and UpToDate. M.E.R. is an inventor of patents owned by Cincinnati Children's.

GTF is a consultant for Shire and founder of EnteroTrack

N.G. is a consultant for Allakos.

Appendix

*List of participants in CEGIR

Given Name	Surname
J.Pablo	Abonia
Seema	Aceves
Samuel	Almonte
Rachel	Andrews
Ashley	Arrington
Nicoleta	Arva
Fred	Atkins
Dominique	Bailey
Alexis	Berry
Bridget	Besl
Scott	Bolton
Peter	Bonis
Wendy	Book
Kimberly	Bray
Teresa	Brown
Cassandra	Burger
Deirdre	Burke
Jonathon	Cahoon
Kelley	Capocelli
Mirna	Cehade
Margaret	Collins
Carla	Davis
Evan	Dellon
Maureen	DeMarshall

Given Name	Surname
Lauren	DiTommaso
Ranjan	Dohil
Michael	Eby
Gary	Falk
David	Fleischer
Heather	Foote
Kelci	Foss
Joel	Friedlander
Patricia	Fulkerson
Glenn	Furuta
Debra	Geno
Nirmala	Gonsalves
Thomas	Greuter
Sandeep	Gupta
Frank	Hamilton
Kirk	Harris
Jennifer	Harris
Ikuo	Hirano
Girish	Hiremath
Nicole	Holland-Thomas
Lea	Jacinto
Amir	Kagalwalla
Timothy	Kaseta
David	Katzka
Kaitlin	Keeley
Emad	Khosh-Hemmat
Paneez	Khoury
Eileen	King
Kara	Kliewer
Amy	Klion
Jennifer	Knowles
Kendra	Kocher
Ellyn	Kodroff
Jeffrey	Krischer
Shay	Kyle
John	Leung
Meredith	Levy
Chris	Liacouras
Denise	Mack
Lisa	Martin
Ellen	Martin
Talaya	McCright-Gill

Given Name	Surname
Paul	Menard-Katcher
Calies	Menard-Katcher
Gabriela	Mendoza
Melissa	Mingler
Mike	Minnicozzi
Amanda	Muir
Vincent	Mukkada
Cristin	MurrayPetzold
Robert	Newbury
Quan	Nhu
Oghenekpaobor (Joel)	Oyibo
Allisa	Paliana
Zhaoxing	Pan
Robbie	Pesek
Kathryn	Peterson
Heidi	Poppendeck
Philip	Putnam
Fabian	Rivera
Marc	Rothenberg
Amanda	Rudman-Spergel
Kathleen	Sable
Alain	Schoepfer
Melissa	Scott
Rachel	Sheridan
Selma	Sinanovic
Jonathan	Spergel
MaryJo	Strobel
Kiki	Sun
Amy	Tasco
Crystal	Tholen
Katherine	Thompson
Tiffany	Tomkinson
Daisy	Tran
Alexandra	Tylicki
Tiina	Urv
Mei-Lun	Wang
Joshua	Wechsler
Barry	Wershil
Lisa	Wheatley
Leah	Wilkey
Guang-Yu	Yang
Angelika	Zalewski

Given Name	Surname
Amy	Zicarelli

Abbreviations

APFED	American Partnership for Eosinophilic Disorders
CEGIR	Consortium of Eosinophilic Gastrointestinal Disease Researchers
COM	Clinical Outcome Metric
CURED	Campaign Urging Research for Eosinophilic Diseases
DMCC	Data Management and Monitoring Center
EC	Eosinophilic Colitis
EFC	Eosinophil Family Coalition
EGID	Eosinophilic Gastrointestinal Disease
EoE	Eosinophilic Esophagitis
EG	Eosinophilic Gastritis
EGE	Eosinophilic Gastroenteritis
EREFS	EoE Reference Score
GERD	Gastroesophageal Reflux Disease
OMEGA	Outcome Metrics for Eosinophilic Gastrointestinal Diseases Across the Ages
PAG	Patient Advocacy Group
PPI	Proton Pump Inhibitor
PRO	Patient-Reported Outcome
RDCRN	Rare Diseases Clinical Research Network
TIGERS	The International Gastrointestinal Eosinophil ResearcherS

References

1. DeBrosse CW, Case JW, Putnam PE, Collins MH, Rothenberg ME. Quantity and distribution of eosinophils in the gastrointestinal tract of children. *Pediatr Dev Pathol.* 2006;9(3):210–8. [PubMed: 16944979]
2. Lowichik A, Weinberg AG. A quantitative evaluation of mucosal eosinophils in the pediatric gastrointestinal tract. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.* 1996;9(2):110–4.

3. Weller PF, Spencer LA. Functions of tissue-resident eosinophils. *Nat Rev Immunol*. 2017;17(12):746–60. [PubMed: 28891557]
4. Kaijser R Zur Kenntnis der allergischen Affektionen des Verdauungskanal vom Standpunkt des Chirurgen aus. *Arch Klin Chir* 1937;188:36–64.
5. Collins MH, Capocelli K, Yang GY. Eosinophilic Gastrointestinal Disorders Pathology. *Frontiers in medicine*. 2017;4:261. [PubMed: 29379785]
6. Jensen ET, Martin CF, Kappelman MD, Dellon ES. Prevalence of Eosinophilic Gastritis, Gastroenteritis, and Colitis: Estimates From a National Administrative Database. *Journal of pediatric gastroenterology and nutrition*. 2016;62(1):36–42. [PubMed: 25988554]
7. Aceves SS. Food allergy testing in eosinophilic esophagitis: what the gastroenterologist needs to know. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*. 2014;12(8):1216–23. [PubMed: 24035776]
8. Aceves SS. Food and aeroallergens in eosinophilic esophagitis: role of the allergist in patient management. *Current opinion in gastroenterology*. 2014;30(4):391–5. [PubMed: 24867155]
9. Aceves SS. Allergy Testing in Patients With Eosinophilic Esophagitis. *Gastroenterol Hepatol (N Y)*. 2016;12(8):516–8. [PubMed: 27917089]
10. Attwood SE, Smyrk TC, Demeester TR, Jones JB. Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome. *Digestive diseases and sciences*. 1993;38(1):109–16. [PubMed: 8420741]
11. Straumann A, Spichtin HP, Bernoulli R, Loosli J, Vogtlin J. [Idiopathic eosinophilic esophagitis: a frequently overlooked disease with typical clinical aspects and discrete endoscopic findings]. *Schweiz Med Wochenschr*. 1994;124(33):1419–29. [PubMed: 7939509]
12. Furuta GT, Liacouras CA, Collins MH, Gupta SK, Justinich C, Putnam PE, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. *Gastroenterology*. 2007;133(4):1342–63. [PubMed: 17919504]
13. Bochner BS, Book W, Busse WW, Butterfield J, Furuta GT, Gleich GJ, et al. Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD). *The Journal of allergy and clinical immunology*. 2012;130(3):587–96. [PubMed: 22935587]
14. Schoepfer AM, Safroneeva E, Bussmann C, Kuchen T, Portmann S, Simon HU, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. *Gastroenterology*. 2013;145(6):1230–6 e1–2. [PubMed: 23954315]
15. Warners MJ, Oude Nijhuis RAB, de Wijkerslooth LRH, Smout A, Bredenoord AJ. The natural course of eosinophilic esophagitis and long-term consequences of undiagnosed disease in a large cohort. *The American journal of gastroenterology*. 2018;113(6):836–44. [PubMed: 29700481]
16. Whelan KA, Godwin BC, Wilkins B, Elci OU, Benitez A, DeMarshall M, et al. Persistent Basal Cell Hyperplasia is Associated with Clinical and Endoscopic Findings in Patients With Histologically Inactive Eosinophilic Esophagitis. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*. 2019.
17. Cheng K, Gupta SK, Kantor S, Kuhl JT, Aceves SS, Bonis PA, et al. Creating a multicenter rare disease consortium - the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). *Transl Sci Rare Dis*. 2017;2(3–4):141–55. [PubMed: 29333363]
18. Gupta SK, Falk GW, Aceves SS, Chehade M, Collins MH, Dellon ES, et al. Consortium of Eosinophilic Gastrointestinal Disease Researchers: Advancing the Field of Eosinophilic GI Disorders Through Collaboration. *Gastroenterology*. 2019;156(4):838–42. [PubMed: 30452923]
19. Spergel JM, Aceves SS, Kliewer K, Gonsalves N, Chehade M, Wechsler JB, et al. New Developments in Eosinophilic Gastrointestinal Diseases Presented at the CEGIR/TIGERS Symposium at the 2018 AAAAI Meeting. *The Journal of allergy and clinical immunology*. 2018.
20. Aceves SS, King E, Collins MH, Yang GY, Capocelli KE, Abonia JP, et al. Alignment of Parent- and Child-Reported Outcomes and Histology in Eosinophilic Esophagitis Across Multiple CEGIR Sites. *The Journal of allergy and clinical immunology*. 2018.
21. Shoda T, Wen T, Aceves SS, Abonia JP, Atkins D, Bonis PA, et al. Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study. *Lancet Gastroenterol Hepatol*. 2018.

22. Spergel JM, Book WM, Mays E, Song L, Shah SS, Talley NJ, et al. Variation in prevalence, diagnostic criteria, and initial management options for eosinophilic gastrointestinal diseases in the United States. *Journal of pediatric gastroenterology and nutrition*. 2011;52(3):300–6. [PubMed: 21057327]
23. Eluri S, Book WM, Kodroff E, Strobel MJ, Gebhart JH, Jones PD, et al. Lack of Knowledge and Low Readiness for Health Care Transition in Eosinophilic Esophagitis and Eosinophilic Gastroenteritis. *Journal of pediatric gastroenterology and nutrition*. 2017;65(1): 53–7. [PubMed: 28644350]
24. Hiremath G, Kodroff E, Strobel MJ, Scott M, Book W, Reidy C, et al. Individuals affected by eosinophilic gastrointestinal disorders have complex unmet needs and frequently experience unique barriers to care. *Clinics and research in hepatology and gastroenterology*. 2018.
25. Aceves SS, Dohil R, Newbury RO, Bastian JF. Topical viscous budesonide suspension for treatment of eosinophilic esophagitis. *The Journal of allergy and clinical immunology*. 2005;116(3):705–6. [PubMed: 16159647]
26. Syverson EP, Hait E, McDonald DR, Rubinstein E, Goldsmith JD, Ngo PD, et al. Oral viscous mometasone is an effective treatment for eosinophilic esophagitis. *J Allergy Clin Immunol Pract*. 2019.
27. McGowan EC, Platts-Mills TAE, Wilson JM. Food allergy, eosinophilic esophagitis, and the enigma of IgG4. *Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology*. 2019;122(6):563–4.
28. Spergel JM. An allergist's perspective to the evaluation of Eosinophilic Esophagitis. *Best practice & research Clinical gastroenterology*. 2015;29(5):771–81. [PubMed: 26552776]
29. Blanchard C, Wang N, Stringer KF, Mishra A, Fulkerson PC, Abonia JP, et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. *J Clin Invest*. 2006;116(2): 536–47. [PubMed: 16453027]
30. Sleiman PM, Wang ML, Cianferoni A, Aceves S, Gonsalves N, Nadeau K, et al. GWAS identifies four novel eosinophilic esophagitis loci. *Nat Commun*. 2014;5:5593. [PubMed: 25407941]
31. Rothenberg ME, Spergel JM, Sherrill JD, Annaiah K, Martin LJ, Cianferoni A, et al. Common variants at 5q22 associate with pediatric eosinophilic esophagitis. *Nat Genet*. 2010;42(4):289–91. [PubMed: 20208534]
32. Beppu LY, Anilkumar AA, Newbury RO, Dohil R, Broide DH, Aceves SS. TGF-beta1-induced phospholamban expression alters esophageal smooth muscle cell contraction in patients with eosinophilic esophagitis. *The Journal of allergy and clinical immunology*. 2014;134(5):1100–7 e4. [PubMed: 24835503]
33. Wen T, Stucke EM, Grotjan TM, Kemme KA, Abonia JP, Putnam PE, et al. Molecular diagnosis of eosinophilic esophagitis by gene expression profiling. *Gastroenterology*. 2013;145(6):1289–99. [PubMed: 23978633]
34. Youngblood BA, Brock EC, Leung J, Falahati R, Bochner BS, Rasmussen HS, et al. Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis. *JCI Insight*. 2019;4(19).
35. Beck LA, Thaci D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. *N Engl J Med*. 2014;371(2):130–9. [PubMed: 25006719]
36. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. *N Engl J Med*. 2018;378(26):2486–96. [PubMed: 29782217]
37. Spergel JM, Rothenberg ME, Collins MH, Furuta GT, Markowitz JE, Fuchs G 3rd, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. *The Journal of allergy and clinical immunology*. 2012;129(2):456–63. 63 e1–3. [PubMed: 22206777]
38. Safroneeva E, Straumann A, Coslovsky M, Zwahlen M, Kuehni CE, Panczak R, et al. Symptoms Have Modest Accuracy in Detecting Endoscopic and Histologic Remission in Adults With Eosinophilic Esophagitis. *Gastroenterology*. 2016;150(3):581–90 e4. [PubMed: 26584601]

39. Safroneeva E, Coslovsky M, Kuehni CE, Zwahlen M, Haas NA, Panczak R, et al. Eosinophilic oesophagitis: relationship of quality of life with clinical, endoscopic and histological activity. *Aliment Pharmacol Ther.* 2015;42(8):1000–10. [PubMed: 26271642]
40. Franciosi JP, Hommel KA, DeBrosse CW, Greenberg AB, Greenler AJ, Abonia JP, et al. Development of a validated patient-reported symptom metric for pediatric eosinophilic esophagitis: qualitative methods. *BMC Gastroenterol.* 2011;11:126. [PubMed: 22099448]
41. Kagalwalla AF, Amsden K, Shah A, Ritz S, Manuel-Rubio M, Dunne K, et al. Cow's milk elimination: a novel dietary approach to treat eosinophilic esophagitis. *Journal of pediatric gastroenterology and nutrition.* 2012;55(6):711–6. [PubMed: 22820121]
42. Kagalwalla AF, Shah A, Li BU, Sentongo TA, Ritz S, Manuel-Rubio M, et al. Identification of specific foods responsible for inflammation in children with eosinophilic esophagitis successfully treated with empiric elimination diet. *Journal of pediatric gastroenterology and nutrition.* 2011;53(2):145–9. [PubMed: 21788754]
43. Kagalwalla AF, Sentongo TA, Ritz S, Hess T, Nelson SP, Emerick KM, et al. Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.* 2006;4(9):1097–102. [PubMed: 16860614]
44. Gonsalves N, Kagalwalla AF. Dietary treatment of eosinophilic esophagitis. *Gastroenterology clinics of North America.* 2014;43(2):375–83. [PubMed: 24813522]
45. Gonsalves N, Yang GY, Doerfler B, Ritz S, Ditto AM, Hirano I. Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. *Gastroenterology.* 2012;142(7):1451–9 e1; quiz e14–5. [PubMed: 22391333]
46. Wang R, Hirano I, Doerfler B, Zalewski A, Gonsalves N, Taft T. Assessing Adherence and Barriers to Long-Term Elimination Diet Therapy in Adults with Eosinophilic Esophagitis. *Digestive diseases and sciences.* 2018.
47. Bedell A, Taft TH, Keefer L, Pandolfino J. Development of the Northwestern Esophageal Quality of Life Scale: A Hybrid Measure for Use Across Esophageal Conditions. *The American journal of gastroenterology.* 2016;111(4):493–9. [PubMed: 26881974]
48. Taft TH, Kern E, Kwiatak MA, Hirano I, Gonsalves N, Keefer L. The adult eosinophilic oesophagitis quality of life questionnaire: a new measure of health-related quality of life. *Aliment Pharmacol Ther.* 2011;34(7):790–8. [PubMed: 21806649]
49. Hirano I, Moy N, Heckman MG, Thomas CS, Gonsalves N, Achem SR. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. *Gut.* 2013;62(4):489–95. [PubMed: 22619364]
50. Hirano I, Dellon ES, Hamilton JD, Collins MH, Peterson K, Chehade M, et al. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. *Gastroenterology.* 2019.
51. Wechsler JB, Bolton SM, Amsden K, Wershil BK, Hirano I, Kagalwalla AF. Eosinophilic Esophagitis Reference Score Accurately Identifies Disease Activity and Treatment Effects in Children. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.* 2017.
52. Warners MJ, Vlieg-Boerstra BJ, Verheij J, van Rhijn BD, Van Ampting MT, Harthoorn LF, et al. Elemental diet decreases inflammation and improves symptoms in adult eosinophilic oesophagitis patients. *Aliment Pharmacol Ther.* 2017;45(6):777–87. [PubMed: 28112427]
53. Mark JA, Anderson BT, Pan Z, Menard-Katcher C, Kramer RE. Comparative Analysis of Adverse Events After Esophageal Balloon and Bougie Dilations in Children. *Journal of pediatric gastroenterology and nutrition.* 2019;68(5):630–4. [PubMed: 30562312]
54. Katzka DA. Esophageal Dilation as the Primary Treatment for Eosinophilic Esophagitis. *Gastroenterol Hepatol (N Y).* 2019;15(6):320–2. [PubMed: 31391800]
55. Richter JE. Endoscopic Treatment of Eosinophilic Esophagitis. *Gastrointest Endosc Clin N Am.* 2018;28(1):97–110. [PubMed: 29129303]
56. Lucendo AJ, Molina-Infante J. Esophageal dilation in eosinophilic esophagitis: risks, benefits, and when to do it. *Current opinion in gastroenterology.* 2018.

57. Jung KW, Gundersen N, Kopacova J, Arora AS, Romero Y, Katzka D, et al. Occurrence of and risk factors for complications after endoscopic dilation in eosinophilic esophagitis. *Gastrointestinal endoscopy*. 2011;73(1):15–21. [PubMed: 21067739]
58. Dellon ES, Gibbs WB, Rubinas TC, Fritchie KJ, Madanick RD, Woosley JT, et al. Esophageal dilation in eosinophilic esophagitis: safety and predictors of clinical response and complications. *Gastrointestinal endoscopy*. 2010;71(4):706–12. [PubMed: 20170913]
59. Ruffner MA, Song L, Maurer K, Shi L, Carroll MC, Wang JX, et al. Toll-like receptor 2 stimulation augments esophageal barrier integrity. *Allergy*. 2019.
60. Masterson JC, Biette KA, Hammer JA, Nguyen N, Capocelli KE, Saeedi BJ, et al. Epithelial HIF-1 α /claudin-1 axis regulates barrier dysfunction in eosinophilic esophagitis. *J Clin Invest*. 2019;129(8):3224–35. [PubMed: 31264974]
61. Simon D, Page B, Vogel M, Bussmann C, Blanchard C, Straumann A, et al. Evidence of an abnormal epithelial barrier in active, untreated and corticosteroid-treated eosinophilic esophagitis. *Allergy*. 2018;73(1):239–47. [PubMed: 28712126]
62. Whelan KA, Merves JF, Giroux V, Tanaka K, Guo A, Chandramouleeswaran PM, et al. Autophagy mediates epithelial cytoprotection in eosinophilic oesophagitis. *Gut*. 2017;66(7):1197–207. [PubMed: 26884425]
63. Ackerman SJ, Kagalwalla AF, Hirano I, Gonsalves N, Katcher PM, Gupta S, et al. One-Hour Esophageal String Test: A Nonendoscopic Minimally Invasive Test That Accurately Detects Disease Activity in Eosinophilic Esophagitis. *The American journal of gastroenterology*. 2019;114(10):1614–25. [PubMed: 31567192]
64. Katzka DA, Geno DM, Ravi A, Smyrk TC, Lao-Sirieix P, Miremadi A, et al. Accuracy, safety, and tolerability of tissue collection by Cytosponge vs endoscopy for evaluation of eosinophilic esophagitis. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*. 2015;13(1):77–83 e2. [PubMed: 24997328]
65. Tabatabaei N, Kang D, Kim M, Wu T, Grant CN, Rosenberg M, et al. Clinical Translation of Tethered Confocal Microscopy Capsule for Unsedated Diagnosis of Eosinophilic Esophagitis. *Sci Rep*. 2018;8(1):2631. [PubMed: 29422678]
66. Nguyen N, Lavery WJ, Capocelli KE, Smith C, DeBoer EM, Deterding R, et al. Transnasal Endoscopy in Unsedated Children With Eosinophilic Esophagitis Using Virtual Reality Video Goggles. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*. 2019;17(12):2455–62. [PubMed: 30708107]
67. Choksi Y, Chaparro J, Blanco M, Sharda R, Sarker S, Ferguson S, et al. Impedance and Histologic Characteristics of the Sub-laryngeal Esophagus Distinguish Eosinophilic Esophagitis From Other Esophageal Disorders. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*. 2019.
68. Menard-Katcher C, Benitez AJ, Pan Z, Ahmed FN, Wilkins BJ, Capocelli KE, et al. Influence of Age and Eosinophilic Esophagitis on Esophageal Distensibility in a Pediatric Cohort. *The American journal of gastroenterology*. 2017;112(9):1466–73. [PubMed: 28508868]
69. Gupta SK, Fitzgerald JF, Chong SK, Croffie JM, Collins MH. Vertical lines in distal esophageal mucosa (VLEM): a true endoscopic manifestation of esophagitis in children? *Gastrointestinal endoscopy*. 1997;45(6):485–9. [PubMed: 9199905]
70. Dellon ES, Liacouras CA, Molina-Infante J, Furuta GT, Spergel JM, Zevit N, et al. Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. *Gastroenterology*. 2018;155(4):1022–33 e10. [PubMed: 30009819]
71. Collins MH, Martin LJ, Alexander ES, Boyd JT, Sheridan R, He H, et al. Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring. *Dis Esophagus*. 2017;30(3):1–8.
72. Collins MH, Dellon ES, Katzka DA, Hirano I, Williams J, Lan L. Budesonide Oral Suspension Significantly Improves Eosinophilic Esophagitis Histology Scoring System Results: Analyses From a 12-Week, Phase 2, Randomized, Placebo-controlled Trial. *The American journal of surgical pathology*. 2019;43(11):1501–9. [PubMed: 31498177]

73. Shoda TWT, Caldwell JM.; Collins MH; Besse JA; Osswald GA; et al. Molecular, Endoscopic, Histologic and Circulating Biomarker-Based Diagnosis of Eosinophilic Gastritis: Multi-Site Study. *The Journal of allergy and clinical immunology*. 2019; in press.
74. Greuter T, Hirano I, Dellon ES. Emerging Therapies for Eosinophilic Esophagitis. *The Journal of allergy and clinical immunology*. 2019.
75. Rothenberg ME, Aceves S, Bonis PA, Collins MH, Gonsalves N, Gupta SK, et al. Working with the US Food and Drug Administration: progress and timelines in understanding and treating patients with eosinophilic esophagitis. *The Journal of allergy and clinical immunology*. 2012;130(3):617–9. [PubMed: 22935588]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 1. Organizational Overview of CEGIR

Legend-The Rare Diseases Clinical Research Network [RDCRN, comprising the Rare Diseases Clinical Research Consortia (RDCRCs), RDCRC Steering Committee, and Data Management Coordinating Center (DMCC)], CEGIR Administrative Core, CEGIR Internal Steering Committee, and CEGIR External Advisory Committee (EAC) provide oversight of CEGIR. Vertical lines represent direct reporting; horizontal and diagonal lines represent collaboration or direct reporting. The CEGIR PI and Director is Marc Rothenberg, MD, PhD and the CEGIR Clinical Team Liaison is Glenn T. Furuta, MD. The CEGIR Pathology Core

members are as follows, with italics indicating leadership: Margaret Collins, MD, Nicoletta Arva, MD, PhD, and Guang-Yu Yang, MD. The CEGIR Biostatistics and Informatics Core members are as follows, with italics indicating leadership: Lisa Martin, PhD, Elizabeth Jensen, MPH, PhD, and Zhaoxing Pan, PhD. The Site Abbreviations are as follows: ACH, Arkansas Children's Hospital; BCM, Baylor College of Medicine; CCHMC, Cincinnati Children's Hospital Medical Center; CHCO, Children's Hospital Colorado; CHOP, Children's Hospital of Philadelphia; CUSOM, Colorado University School of Medicine; Lurie Children's, Lurie Children's Hospital of Chicago; Mt. Sinai, Icahn School of Medicine at Mount Sinai; Northwestern, Northwestern University; NIH, National Institutes of Health; Tufts, Tufts Medical Center; UCSD, University of California, San Diego; UI-Peoria, University of Illinois College of Medicine at Peoria; UNC, University of North Carolina; UPenn, University of Pennsylvania; UU, University of Utah; Vanderbilt, Vanderbilt University. The Site Investigators are as follows, with italics designating CEGIR Site Leaders: ACH, Robert Pesek, MD; BCM, Carla McGuire Davis, MD and Anthony Olive, MD; CCHMC, Marc Rothenberg, MD, PhD, Vince Mukkada, MD, J. Pablo Abonia, MD, Philip Putnam, MD, and Ting Wen, MD, PhD; CHCO, Glenn T. Furuta, MD, Dan Atkins, MD, and Calies Menard-Katcher, MD; CHOP, Jonathan Spergel, MD and Amanda Muir, MD; CUSOM, Paul Menard-Katcher, MD; Lurie Children's, Joshua Wechsler, MD, Barry Wershil, MD, and Amir Kagalwalla, MD; Mt. Sinai, Mirna Chehade, MD; Northwestern, Ikuo Hirano, MD and Nirmala Gonsalves, MD; NIH, Amy Klion, MD and Pannez Khoury, MD; Tufts, John Leung, MD and Peter Bonis, MD; UCSD, Seema Aceves, MD, PhD; UI-Peoria, Sandeep Gupta, MD; UNC, Evan Dellon, MD; UPenn, Gary Falk, MD; UU, Kathryn Peterson, MD; Vanderbilt, Girish Hiremath, MPH, MD. PAG, patient advocacy group.

Table 1.

Factors contributing to CEGIR progress

Developing longstanding collegial relationships between investigators based on mutual respect and long-term vision
Creating a multidisciplinary approach to research that involves allergists, gastroenterologists, pathologists, dietitians, epidemiologists, clinician researchers, basic researchers, and statisticians to understand different aspects of the EGIDs
Involving pediatric and adults specialists to understand the natural history of EGIDs
Engaging with multiple patient advocacy groups (PAGs) to increase awareness of the patient perspective and the importance of research and to develop patient-friendly research
Building close relationships with academic societies and institutional leadership to promote research and garner support
Partnering with NIH experts to carry out cooperative research
Leveraging the expertise of the RDCRN and the 20 associated consortia
Maintaining regular and frequent communication with the NIH, NIAID, NIDDK, and NCATS program officials to conduct research in a robust fashion
Partnering with industry to develop and execute cutting-edge research studies
Fostering relationships with the Food and Drug Administration, Department of Health and Human Services and governmental officials to educate about EGIDs and understand regulatory and compliance aspects of therapeutics developments (75)

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2.

Clinically Relevant CEGIR Products

Major Advances	Benefit of Advance
Development and Validation of EoE Histological Scoring System	Extends pathological analysis beyond eosinophil counts alone; provides tool for clinical trials.
Whole Slide Imaging of Pathology Slides	Allows convenient image transfer, offsite microscopy and central pathological analyses
Identification of EoE Endotypes	Stratifies patients into clinically significant and potentially therapeutically distinct subgroups
Validation and Refinement of Patient Reported Outcomes (PROs)	Allows quantitative assessment of patient wellbeing, and parent-by-proxy monitoring
Refinement of Disease Characteristics	Largest analyses of EC, rarest form of EGID, uncovering new clinical associations
Development of EG Diagnostic Panel and Blood Panel ⁷³	Assesses disease pathogenesis, defines molecular-clinical and endoscopic correlates, and provides opportunity for non-invasive biomarkers.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript